Hims & Hers (HIMS) Gets a New Chief Accounting Officer as Legal and Regulatory Pressure Builds
As seen on the 24/7 Wall St. homepage on October 15, 2026.
A fresh Form 3 from the person who signs off on the books lands as Hims & Hers fights Novo Nordisk in court and the FDA tightens compounded GLP-1 rules. Accounting leadership changes at a $6.6 billion company whose revenue recognition is under a microscope are worth tracking filing by filing.
Continue ReadingShow less
Jonathan M. Franklin filed a Form 3 with the SEC on October 15, 2026, establishing his initial ownership position as the newly appointed Chief Accounting Officer of Hims & Hers Health. A Form 3 is the required first disclosure any officer or director must submit when they become an insider at a public company, so this filing marks the formal start of Franklin's trackable insider record at the $6.6 billion company.
The timing is notable. Hims & Hers is currently engaged in litigation against Novo Nordisk while also navigating a tightening regulatory environment around compounded GLP-1 medications from the FDA. The person responsible for overseeing the accuracy of the company's financial statements is stepping into that role at one of the more consequential moments in the company's history.
Revenue recognition is a particular area of scrutiny for a company whose business model involves compounded drugs, subscription health services, and evolving product mix. How those revenue streams are classified and reported falls squarely within the Chief Accounting Officer's domain, making any change in that seat meaningful for investors who follow the financials closely.
Form 3 filings carry no information about compensation, share grants, or options. Those details will appear in subsequent Form 4 filings whenever Franklin buys, sells, or receives equity. Watching those follow-on disclosures will give a clearer picture of how he is being compensated and how aligned his financial interests are with shareholders.
Sources
Mentioned: HIMS